Opens in a new tab
Tuesday, 17 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Disease & Drugs

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Disease & Drugs

1,785 stories · every one Fact-Checked
DementiaClinical TrialsNeflamapimod Delivers Clinical and Biomarker Benefits in Dementia with Lewy Bodies: Key Findings from the Phase 2b RewinD-LB TrialDementia with Lewy bodies (DLB) is a common type of neurodegenerative dementia. It is marked by fluctuating cognition, visual hallucinations, Parkinsonian movement symptoms, and early problems with attention.…12 Oct 2025 · 5 min read
Fact-Checked
TDClinical TrialsValbenazine from KINECT-PRO Study Delivers Superior Well-Being Results for Tardive Dyskinesia: Post-Marketing Data from MDS Congress 2025Tardive dyskinesia (TD) remains a persistent movement disorder affecting patients exposed to long-term antipsychotic medications and other dopamine antagonists.11 Oct 2025 · 3 min read
Fact-Checked
GCTFClinical TrialsWHO Launches Global Clinical Trials Forum to Boost Worldwide Health ResearchOn 7 October 2025, the World Health Organization officially launched the Global Clinical Trials Forum (GCTF), an initiative aimed at raising global standards for clinical research, harmonizing practices…11 Oct 2025 · 5 min read
Fact-Checked
simponiNew Drug ApprovalFDA Clears Simponi (Golimumab) for Children with Ulcerative ColitisThe U.S. Food and Drug Administration (FDA) has approved Simponi (Golimumab) for the treatment of children aged two years and older with moderately to severely active ulcerative colitis…10 Oct 2025 · 5 min read
Fact-Checked
jascaydNew Drug ApprovalJascayd (Nerandomilast) Receives FDA Nod for Idiopathic Pulmonary FibrosisThe U.S. Food and Drug Administration (FDA) have approved Jascayd (Nerandomilast) tablets for the treatment of idiopathic pulmonary fibrosis (IPF) in adults.10 Oct 2025 · 4 min read
Fact-Checked
zoryveClinical TrialsFDA Approves Arcutis’ Zoryve (Roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5On October 3, 2025, the U.S. Food and Drug Administration (FDA) approved Zoryve® (roflumilast) Cream 0.05%, developed by Arcutis Biotherapeutics, Inc., for the treatment of mild to moderate…9 Oct 2025 · 5 min read
Fact-Checked
InhalerResearchJAMA Study Finds Asthma Inhalers Have a Carbon Footprint Equal to 530,000 Cars a YearInhalers play a central role in managing asthma and chronic obstructive pulmonary disease (COPD).9 Oct 2025 · 5 min read
Fact-Checked
ZaynichResearchWhat Is Wockhardt’s New Drug Zidebactam? A Groundbreaking Beta-Lactam Enhancer in the Fight against SuperbugsZAYNICH, also known as WCK-5222, is a novel antibiotic researched and developed by the Indian pharmaceutical company Wockhardt as a strategic response to the growing global crisis of…8 Oct 2025 · 7 min read
Fact-Checked
Gemini_Generated_Image_iub741iub741iub7-logo_11zonResearch2025 Nobel Prize in Physiology or Medicine: Pioneering Discoveries in Immune Tolerance and Regulatory T CellsThe Nobel Prize in Physiology or Medicine 2025 was awarded jointly to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their pioneering discoveries concerning peripheral immune tolerance…7 Oct 2025 · 5 min read
Fact-Checked
lithiumResearchRethinking Lithium: A Potential Therapeutic Avenue in Alzheimer’s diseaseDefence Services Medical Research Centre, Naypyitaw, Myanmar…7 Oct 2025 · 13 min read
Fact-Checked
ETX-636Clinical TrialsFDA Fast Tracks ETX‑636: New Hope for PIK3CA-Mutant Advanced Breast CancerEnsem Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug ETX-636 for the treatment of PIK3CA-mutant, hormone…7 Oct 2025 · 4 min read
Fact-Checked
ZelicapavirClinical TrialsPositive Phase 2b Results of Enanta’s Zelicapavir in High-Risk Adults with RSV: A Promising Advancement in Antiviral TherapyEnanta Pharmaceuticals recently announced highly encouraging Phase 2b clinical trial results for zelicapavir, an investigational oral antiviral drug, in treating respiratory syncytial virus (RSV) infection in high-risk adult…6 Oct 2025 · 4 min read
Fact-Checked
Page 137 of 149